EUVIMEDEUVIMED entdecken
Crossref

Pharmacie clinique oncologique : état des lieux national relatif aux interventions pharmaceutiques en unité de production des anticancéreux en 2024

Caroline Streicher, Florence Ranchon, Florian Slimano, Wakil Azouza, Aude Berroneau, Guillaume Sicard, Amandine Baudoin, Jean-François Tournamille, Régine Chevrier, Bertrand Pourroy, Raphaëlle Fanciullino

Annales Pharmaceutiques Françaises · 2026-03 · 84 (2) · 277-284

DOI: 10.1016/j.pharma.2025.10.007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annales Pharmaceutiques Françaises, 2026-03. Verfasst von Caroline Streicher und 10 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacie, centre hospitalier de Brive, 1, boulevard du Dr-Verlhac, 19312 Brive-la-Gaillarde cedex, France; Société française de pharmacie oncologiqu…. Hauptthemen laut MEDLINE: Pharmacy Service, Hospital, Antineoplastic Agents, Medical Oncology. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pharmaceutical analysis of injectable anticancer drug prescriptions is a key component of patient safety and therapeutic optimization within compounding units. This process often leads to pharmaceutical interventions (PI), but their coding and recognition remain highly variable across healthcare institutions. Evaluating current practices related to PI in oncology production units, identifying barriers to their documentation, and determining pharmacists' needs are major challenges. A national survey was conducted by the French Society for Oncology Pharmacy (SFPO) using an online questionnaire. The survey was structured around four themes: institutional characteristics, levels of clinical pharmacy analysis, PI, and PI management. Data were analyzed descriptively. A total of 104 healthcare institutions participated in the study. Level 2 or 3 pharmaceutical analyses were performed in 89% of the centers. The pharmaceutical analysis leading to a PI was recorded in 61% of cases. Due to a lack of appropriate tools, 50% of respondents reported that they do not code their PI. The clinical, economic, or organizational impact of PI was rarely assessed. Notably, 96% of respondents felt that PI are not sufficiently recognized, and 93% expressed a strong need for a dedicated, interoperable coding tool. This survey highlights the relevance of developing a tool to facilitate the coding and traceability of PI, in order to better valorize this specific pharmaceutical expertise.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pharmacy Service, HospitalAntineoplastic AgentsMedical OncologyFranceHumansSurveys and QuestionnairesPharmacistsDrug Compounding

Stichwörter der Autor:innen

CancerologyCancérologieClinical pharmacyIntervention pharmaceutiquePharmaceutical interventionsPharmacie clinique

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Pharmacie, centre hospitalier de Brive, 1, boulevard du Dr-Verlhac, 19312 Brive-la-Gaillarde cedex, France; Société française de pharmacie oncologique, 37, rue des Mathurins, 75008 Paris, France. Electronic address: car…
  • Société française de pharmacie oncologique, 37, rue des Mathurins, 75008 Paris, France; Pharmacie, centre hospitalier Lyon Sud, 69495 Pierre-Bénite, France.
  • Société française de pharmacie oncologique, 37, rue des Mathurins, 75008 Paris, France; Pharmacie, CHU de Reims, Reims, France.
  • Société française de pharmacie oncologique, 37, rue des Mathurins, 75008 Paris, France; Pharmacie, hôpital privé Arnault-Tzanck, 06250 Mougins, France.
  • Pharmacie, groupe Sud, CHU de Bordeaux, 33600 Pessac, France.
  • Société française de pharmacie oncologique, 37, rue des Mathurins, 75008 Paris, France; Unité Oncopharma, CHU La Timone, AP-HM, 13005 Marseille, France.

Zitieren

APA

Streicher, C., Ranchon, F., Slimano, F., Azouza, W., Berroneau, A., Sicard, G., Baudoin, A., Tournamille, J. F., Chevrier, R., Pourroy, B., & Fanciullino, R. (2026). Pharmacie clinique oncologique : état des lieux national relatif aux interventions pharmaceutiques en unité de production des anticancéreux en 2024. Annales Pharmaceutiques Françaises, 84(2), 277-284. https://doi.org/10.1016/j.pharma.2025.10.007

Vancouver

Streicher C, Ranchon F, Slimano F, Azouza W, Berroneau A, Sicard G, et al. Pharmacie clinique oncologique : état des lieux national relatif aux interventions pharmaceutiques en unité de production des anticancéreux en 2024. Annales Pharmaceutiques Françaises. 2026;84(2):277-284. doi:10.1016/j.pharma.2025.10.007

BibTeX
@article{Streicher2026,
  author = {Streicher, Caroline and Ranchon, Florence and Slimano, Florian and Azouza, Wakil and Berroneau, Aude and Sicard, Guillaume and Baudoin, Amandine and Tournamille, Jean-François and Chevrier, Régine and Pourroy, Bertrand and Fanciullino, Raphaëlle},
  title = {Pharmacie clinique oncologique : état des lieux national relatif aux interventions pharmaceutiques en unité de production des anticancéreux en 2024},
  journal = {Annales Pharmaceutiques Françaises},
  year = {2026},
  volume = {84},
  number = {2},
  pages = {277--284},
  doi = {10.1016/j.pharma.2025.10.007}
}
Kostenlos starten →